MAR 09, 2021 1:15 AM PST

Personalized Psychedelic Assisted-Therapy

WRITTEN BY: Nouran Amin

Psychedelics have long been known for their therapeutic in treating mental health disorders. However, there remains a concern that patients in clinical trials may have adverse effects to these drugs. In fact, a recent study has shown personality traits associated with the negative/positive experiences of psychedelic use. These findings may inform how participants in clinical trials respond to these substances.  

"The findings point to interesting testable things we can look at in future research," said Alan Davis, assistant professor of social work at The Ohio State University and senior author of the review. "It might be plausible to use threshold doses that are smaller than those used in a trial as a first exposure so people have less anxiety, experience the benefit and, from that, go into a higher dose later."

Results were published in the journal ACS Pharmacology & Translational Science.

"It's been an open question so far in psychedelic science: How can we predict how people will react? We thought this review would be a good opportunity to develop a narrative of what the consensus is so far," said study first author Jacob Aday, a PhD candidate in psychology at Central Michigan University who collaborates with Davis.

Learn more about psychedelics:

"Psychedelics might broadly apply to a whole range of different psychiatric problems, and in part that might be because they're directly affecting neurotransmission and the brain's ability to communicate in new ways that involve different parts of the brain," Davis said. "But there is still a lot to unpack about exactly how this all works and why it may be effective."

Source: Science Daily

 

About the Author
  • Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
JAN 24, 2021
Cannabis Sciences
Cannabis Compound CBD Shows Promise as Antibiotic
JAN 24, 2021
Cannabis Compound CBD Shows Promise as Antibiotic
Researchers from the University of Queensland, in collaboration with Botanix Pharmaceuticals Limited, have found that ca ...
JAN 20, 2021
Drug Discovery & Development
Designer Cytokine: Potential Therapeutic Approach for Paralysis
JAN 20, 2021
Designer Cytokine: Potential Therapeutic Approach for Paralysis
Paralysis due to spinal cord damage remains an irreparable condition. However, a new therapeutic approach may bring rene ...
FEB 10, 2021
Drug Discovery & Development
Genetics Affect Response to Cancer Immunotherapy
FEB 10, 2021
Genetics Affect Response to Cancer Immunotherapy
Researchers have found that genetic factors may dictate as much as 20% of the efficacy of checkpoint inhibitors, a kind ...
APR 01, 2021
Immunology
Tumor-Killing 101: Vaccine Trains Immune Cells to Keep Skin Cancer at Bay
APR 01, 2021
Tumor-Killing 101: Vaccine Trains Immune Cells to Keep Skin Cancer at Bay
Cancer researchers have developed a therapeutic vaccine for melanoma, a deadly form of skin cancer. Instead of protectin ...
APR 13, 2021
Immunology
The "Unexpected" Reason Why COVID Antivirals Don't Work
APR 13, 2021
The "Unexpected" Reason Why COVID Antivirals Don't Work
Purdue University researchers have made a breakthrough finding that could explain why the disease is so hard to manage t ...
MAY 03, 2021
Drug Discovery & Development
Low Dose Radiation May Improve Symptoms of Alzheimer's
MAY 03, 2021
Low Dose Radiation May Improve Symptoms of Alzheimer's
While high doses of radiation are known to be harmful, low doses may be able to help the body protect and repair. And no ...
Loading Comments...